Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor α to vinblastine and vinorelbine

Breast Cancer Research and Treatment

Volumn 121, Issue 2, 2010, Pages 335-345

  Sui, Meihua ^a,b   Jiang, Donghai ^a   Hinsch, Claire ^b   Fan, Weimin ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Breast cancer; Estrogen receptor; Fulvestrant; Vinorelbine

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; I KAPPA B ALPHA; NAVELBINE; PROTEIN BCL 2; VINBLASTINE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SEPARATION; DNA FRAGMENTATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; FLOW CYTOMETRY; HUMANS; TRANSFECTION; VINBLASTINE;

EID: 77953021622     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0472-4     Document Type: Article

References (40)

1. Paik S, Hartmann DP, Dickson RB, Lippman ME (1994) Antiestrogen resistance in ER positive breast cancer cells. Breast Cancer Res Treat 31:301-307 (Pubitemid 24323470)
2. Kurebayashi J (2003) Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance. Breast Cancer 10:112-119
3. Murphy L, Cherlet T, Lewis A, Banu Y, Watson P (2003) New insights into estrogen receptor function in human breast cancer. Ann Med 35:61.4-631. (Pubitemid 38005317)
4. Maehara Y, Emi Y, Sakaguchi Y, Kusumoto T, Kakeji Y, Kohnoe S, Sugimachi K (1990) Estrogen-receptor-negative breast cancer tissue is chemosensitive in vitro compared with estrogen-receptor-positive tissue. Eur Surg Res 22:50-55 (Pubitemid 20181315)
5. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ (2003) Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 88:406-412 (Pubitemid 36308152)
6. Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HM, Aitken SC, Warren R (1978) The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223-1228 (Pubitemid 9054222)
7. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein U, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667
8. Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, Slack R, Hayes DF (2003) A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 9:124-133
9. Cocquyt VF, Schelfhout VR, Blondeel PN, Depypere HT, Daems KK, Serreyn RF, Praet MM, Van Belle SJ (2003) The role of biological markers as predictors of response to preoperative chemotherapy in large primary breast cancer. Med Oncol 20:221-231
10. Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930-942
11. Beck WT, Cass CE, Houghton PJ (1997) Anticancer drugs from plants: vinca alkaloids and taxanes. In: Holland JF, Frei EIlI, Bast RC, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer medicine, 4th edn. Williams and Wilkins, Baltimore, pp 1005-1014
12. Gidding CE, Kellie SJ, Kamps WA, de Graaf SS (1999) Vincristine revisited. Crit Rev Oncol Hematol 29:267-287
13. Rowinsky EK, Donehower RC (1991) The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 52:35-84
14. Jordan MA, Thrower D, Wilson L (1991) Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res 51:2212-2222
15. Himes RH (1991) Interactions of the catharanthus (vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 51:257-267
16. Huang Y, Fang Y, Wu J, Dziadyk JM, Zhu X, Sui M, Fan W (2004) Regulation of vinca alkaloid-induced apoptosis by NF-κB/IκB pathway in human tumor cells. Mol Cancer Ther 3:271-277
17. Johnson KR, Young KK, Fan W (1999) Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy. Clin Cancer Res 5:2559-2565
18. Fan M, Goodwin ME, Birrer MJ, Chambers TC (2001) The c-Jun NH(2)-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine. Cancer Res 61:4450-4458
19. Luqmani YA (2005) Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14(Suppl 1):35-48
20. Huang Y, Johnson KR, Norris JS, Fan W (2000) Nuclear factor-kappaB/ IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 60:4426-4432
21. Sui M, Chen F, Chen Z, Fan W (2006) Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int J Cancer 119:712-717
22. Fan W, Cheng L, Norris JS, Willingham MC (1996) Glucocorticoids selectively inhibit taxol-induced apoptosis in a human breast cancer cell line. Cell Pharmacol 3:435-440
23. Fan W, Sui M, Huang Y (2004) Glucocorticoids selectively inhibit paclitaxel-induced apoptosis: mechanisms and its clinical impact. Curr Med Chem 11:403-411
24. Sui M, Huang Y, Park BH, Davidson NE, Fan W (2007) Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res 67:5337-5344
25. Osborne CK, Zhao H, Fuqua SA (2000) Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 18:3172-3186
26. Robertson JF (2001) Faslodex (ICI 182, 780), a novel estrogen receptor downregulator-future possibilities in breast cancer. J Steroid Biochem Mol Biol 79:209-212
27. Abukhdeir AM, Blair BG, Brenner K, Karakas B, Konishi H, Lim J, Sahasranaman V, Huang Y, Keen J, Davidson N, Vitolo MI, Bachman KE, Park BH (2006) Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells. Breast Cancer Res Treat 99:23-33
28. Huang Y, Keen JC, Pledgie A, Marton LJ, Zhu T, Sukumar S, Park BH, Blair B, Brenner K, Casero RA Jr, Davidson NE (2006) Polyamine analogues down-regulate estrogen receptor alpha expression in human breast cancer cells. J Biol Chem 281:19055-19063
29. Sui M, Dziadyk JM, Zhu X, Fan W (2004) Cell cycle-dependent antagonistic interactions between paclitaxel and gamma-radiation in combination therapy. Clin Cancer Res 1.0:4848-4857
30. Sui M, Fan W (2005) Combination of gamma-radiation antagonizes the cytotoxic effects of vincristine and vinblastine on both mitotic arrest and apoptosis. Int J Radiat Oncol Biol Phys 61:1151-1158
31. Cheng L, Zheng S, Raghunathan K, Priest DG, Willingham MC, Norris JS, Fan W (1995) Characterisations of Taxol-induced apoptosis and altered gene expression in human breast cancer cells. Cell Pharmacol 2:249-257
32. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry, J Immunol Methods 139:271-279
33. Fan W, Schandl CA, Cheng L, Norris JS, Willingham MC (1996) Glucocorticoids modulate Taxol cytotoxicity in human solid tumor cells. Cell Pharmacol 3:343-348
34. Wu L, Tannock IF (2005) Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy. Clin Cancer Res 11:8195-8200
35. Chen D, Hackl W, Ortmann O, Treeck O (2004) Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro. Anticancer Drugs 15:55-61. (Pubitemid 39140173)
36. Nole F, Minchella I, Colleoni M, Orvieto E, Munzone E, de Braud F, Peruzzotti G, Martinelli G, Zampino MG, Catania C, Pizzamiglio M, Veronesi P, Zurrida S, Galimberti V, Goldhirsch A, Veronesi U (1999) Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). Ann Oncol 10:993-996
37. Wang L, Jiang Z, Sui M, Shen J, Xu C, Fan W (2009) The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study. BMC Cancer 9:226
38. Martin LA, Pancholi S, Chan CM, Farmer I, Kimberley C, Dowsett M, Johnston SR (2005) The anti-oestrogen ICI 182, 780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signaling. Endocr Relat Cancer 12:1017-1036
39. Pathan N, Aime-Sempe C, Kitada S, Basu A, Haldar S, Reed JC (2001) Microtubule-targeting drugs induce bcl-2 phosphorylation and association with Pinl. Neoplasia 3:550-559
40. Wang LG, Liu XM, Kreis W, Budman DR (1999) The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44:355-361